Novavax sees weak Covid vaccine sales
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand for five-component acellular pertussis (5-acP) antigen. Due for completion ...
Sanofi’s third-quarter results showed the company’s pharma and vaccines businesses grew faster and were more profitable than its consumer-health unit Opella.
While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...
Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus ...
Sanofi Pasteur is improving global human health by the discovery, development, manufacture and supply of vaccines for the prevention and treatment of infectious diseases. Sanofi Pasteur has a ...
Vaccines sales rose a currency-adjusted 25.5% to 3.8 billion euros in the quarter, ahead of a 3.2 billion euro analyst consensus. Sanofi is nearing a sale of a 50% stake in its consumer unit ...
Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales ...
The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback